[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].

Q3 Medicine Revista alergia Mexico Pub Date : 2023-01-04 DOI:10.29262/ram.v69i2.1088

Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez

{"title":"[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].","authors":"Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez","doi":"10.29262/ram.v69i2.1088","DOIUrl":null,"url":null,"abstract":"Background: The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.Case report: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.Conclusions: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"69 2","pages":"89-92"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v69i2.1088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.

Case report: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.

Conclusions: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[皮肤试验证明对辉瑞- biontech®疫苗过敏]。

背景:辉瑞- biontech®BNT162b2疫苗从第二剂开始提供95%的有效性。报告的COVID-19疫苗过敏反应率为4.7例/百万剂。病例报告:30岁女性，卫生专业人员，变应性鼻炎、哮喘病史，眼部化妆品及胶布反应:红斑、水肿、局部瘙痒。在使用第一剂辉瑞- biontech疫苗后，她立即出现了III级过敏反应。对患者进行分层，分型，PEG 3350皮肤试验呈阳性。建议不要重新使用含有聚乙二醇的疫苗，并提供了替代品。结论:高危人群首次接种基于mrna的COVID-19疫苗前应进行充分的风险分层。在首次给药时出现过敏反应的情况下，应进行表型分析和PEG皮肤试验的进一步研究，并提供替代疫苗接种。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊